Subjects of human abuse potential (HAP) studies must be able to detect liking with the investigational drug. However, many subjects recruited for HAP studies use marijuana, and THC is often exempt from exclusion by urine drug tests (UDTs). PRA Health Sciences examined whether UDT evidence of recent marijuana use was associated with a difference in subjects’ ability to discriminate opioid from placebo. Successful opioid discriminators were associated with a statistically insignificant, but higher positive THC UDT rate and mean carboxy-THC urine concentration when compared to non-discriminators, indicating that recent users of marijuana may not need to be excluded from opioid HAP studies.
We’re committed to meaningfully integrating sustainability considerations into our business practices and culture. The work we do has a global…
PRA Successfully Delivers A Complex Phase I Psoriasis Study
Exceptional Support and Innovative Strategies Combat Study Challenges.
Real-World Misuse Abuse and Dependence of Abuse Deterrent
Abuse deterrent formulations of opioid medications (ADOs) may help curtail the widespread abuse, misuse, and diversion of these products.With the…